The value of pretreatment glucose-to-lymphocyte ratio for predicting survival of metastatic gastric cancer
Future Oncology · 2023-02 · 19 (4) · 315-325
DOI: 10.2217/fon-2022-0579 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Oncology, online erschienen am 09.03.2023. Verfasst von Zekeriya Hannarici und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Atatürk University Faculty of Medicine, Erzurum, 25100, Turkey. Hauptthemen laut MEDLINE: Glucose, Stomach Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
Aim
To demonstrate the prognostic importance of glucose-to-lymphocyte ratio (GLR) in metastatic gastric cancer (mGC).
Methods
Retrospectively, 159 mGC patients were enrolled. Kaplan-Meier curve and Cox regression analysis were used to determine the prognostic value of the systemic immune inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), prognostic nutritional index (PNI) and GLR.
Results
Progression-free survival (PFS) and overall survival (OS) were associated with NLR, PNI, SII and GLR by univariate analysis. Moreover, OS was associated with Eastern Cooperative Oncology Group performance status and the chemotherapy regimen. In multivariate analysis, only GLR was found to be independently prognostic for both PFS and OS.
Conclusion
In mGC, GLR may be a new prognostic marker for both OS and PFS. Gastric cancer (GC) is the fourth cause of cancer-related deaths. Although different treatment algorithms, including immunotherapy, are applied in patients with unresectable or disseminated (metastatic) GC (mGC), survival results are not yet at the desired level. Different markers are being investigated to measure the response of cancer to treatment in these patients. Many studies have been conducted in this direction with the thought that the prognosis of these cancers will be affected by the patient's own immune response and nutritional status. Despite this, standard markers have not been established to predict cancer-related survival. Studies have shown a relationship between GC and glucose metabolism processes. Recently, a fasting blood glucose-to-lymphocyte count ratio (GLR) marker was developed that simultaneously evaluates both glucose metabolism and the patient's immune response. GLR was found to be effective in predicting survival time in cancers such as gallbladder cancer and hepatocellular carcinoma. However, the effect of GLR on survival in mGC is unclear. In this study, the authors investigated the prognostic significance of GLR in mGC. They found that low GLR was associated with longer survival in mGC. GLR may be a prognostic marker for survival in patients with mGC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Atatürk University Faculty of Medicine, Erzurum, 25100, Turkey.
- Department of Medical Oncology, Health Sciences University Mehmet Akif İnan Training & Research Hospital, Şanlıurfa, 63040, Turkey.
ORCID-Profile: Zekeriya Hannarici, Ali Yılmaz
Zitieren
APA
Hannarici, Z., Yılmaz, A., Buyukbayram, M. E., Turhan, A., Çağlar, A. A., Bilici, M., & Tekin, S. B. (2023). The value of pretreatment glucose-to-lymphocyte ratio for predicting survival of metastatic gastric cancer. Future Oncology, 19(4), 315-325. https://doi.org/10.2217/fon-2022-0579
Vancouver
Hannarici Z, Yılmaz A, Buyukbayram ME, Turhan A, Çağlar AA, Bilici M, et al. The value of pretreatment glucose-to-lymphocyte ratio for predicting survival of metastatic gastric cancer. Future Oncology. 2023;19(4):315-325. doi:10.2217/fon-2022-0579
BibTeX
@article{Hannarici2023,
author = {Hannarici, Zekeriya and Yılmaz, Ali and Buyukbayram, Mehmet Emin and Turhan, Aykut and Çağlar, Alperen Akansel and Bilici, Mehmet and Tekin, Salim Başol},
title = {The value of pretreatment glucose-to-lymphocyte ratio for predicting survival of metastatic gastric cancer},
journal = {Future Oncology},
year = {2023},
volume = {19},
number = {4},
pages = {315--325},
doi = {10.2217/fon-2022-0579}
}
EUVIMED